The SARS-CoV-2 (2019-nCoV) Nucleocapsid (N) is a structural protein that plays an important role in viral life cycle including replication, transcription, and genome packaging. N-protein, being one of the predominantly expressed proteins at the early stage of SARS-CoV infection, and detection efficiency of the N-protein is significantly higher than SARS-CoV specific IgG, SARS-CoV RNA markers, simultaneously, so N-protein has been an attractive tool for early diagnosis. N-protein has also been tested as a protective vaccine against SARS-CoV infection. So SARS-COV-2(2019-nCoV) N Protein can be used not for diagnosis, it could also be a potential vaccine candidate to against 2019-nCov/COVID.
Pre-made products list
|
Cat.# |
Vector Name |
Price |
|
AC250-02 |
SARS-COV-2(2019-nCoV) N Protein , His Tag Recombinant Protein |
$300 for 100ug |
|
AC250-02 |
SARS-COV-2(2019-nCoV) N Protein , His Tag Recombinant Protein |
$300 for 100ug |
|
AC250-03 |
SARS-COV-2(2019-nCoV) N Protein , His Tag Recombinant Protein |
$300 for 100ug |
Product Details
Size 0.5ml
Concentration 2mg/ml
Class Recombinant
Type Protein
Form Liquid
Purification SDS-PAGE
Storage Buffer PBS, pH 5.7
Storage Conditions Store the liquid protein at -20°C or -80°C for long term, 4 ℃ for short-term storage.
Reconstitution Reconstitute to a new concentration in PBS. Repeated freeze-thaw cycles should be avoided.
Product Specific Information
• Molecular Weight: 48 kDa
• Animal Origin Free: Yes
• Protein Length: SARS-COV-2(2019-nCoV) N protein fused with a 6×His tag at the C-terminus and N-terminus, respectively.
• Purity: 90%±5% by SDS-PAGE.
• Biological Activity: Measured by colloidal gold method. The activity was better and the detection limit was lower.
L1, L2 and L3 are respectively diluted samples of IgM and IgG positive samples ( L1: 256 fold dilution; L2: 512 fold dilution; L3:1024 fold dilution; L4: dilution buffer).
• Clinical verifications
The performance of the Dablood SARS-CoV-2 IgG / IgM Antibody Test was compared to a composite reference method that includes a RT-PCR method and a chemiluminescence immunosorbent assay (CLIA). Positive Percent Agreement (PPA) is 89.5%, the Negative Percent Agreement (NPA) is 99.7% and the Total Percent Agreement is 95%.
Applications
• Vaccination studies
• Antibody screening
• Inhibitor screening
sales@brainvta.com
Return to top